Financhill
Sell
34

PRPH Quote, Financials, Valuation and Earnings

Last price:
$0.33
Seasonality move :
9.49%
Day range:
$0.32 - $0.40
52-week range:
$0.22 - $5.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.97x
P/B ratio:
1.83x
Volume:
1.6M
Avg. volume:
1.7M
1-year change:
-93.63%
Market cap:
$13.4M
Revenue:
$6.8M
EPS (TTM):
-$1.54

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRPH
ProPhase Labs
$2.5M -$0.18 -32.58% -48.57% $13.80
APDN
Applied DNA Sciences
$1.2M -$3.00 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
OCX
OncoCyte
$126.8K -$0.25 180.72% -33.33% $4.42
VCYT
Veracyte
$111M $0.20 6.44% 332.6% $40.50
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRPH
ProPhase Labs
$0.32 $13.80 $13.4M -- $0.00 0% 0.97x
APDN
Applied DNA Sciences
$0.65 -- $712.2K -- $0.00 0% 0.04x
FONR
Fonar
$13.51 -- $85.1M 10.81x $0.00 0% 0.83x
OCX
OncoCyte
$2.80 $4.42 $80.1M -- $0.00 0% 12.69x
VCYT
Veracyte
$29.00 $40.50 $2.3B 70.73x $0.00 0% 4.95x
XWEL
XWELL
$0.93 -- $4.9M -- $0.00 0% 0.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRPH
ProPhase Labs
31.06% -4.436 37.21% 1.12x
APDN
Applied DNA Sciences
-- 5.301 -- 4.28x
FONR
Fonar
-- 1.233 -- 9.69x
OCX
OncoCyte
-- -1.798 -- 3.57x
VCYT
Veracyte
-- 3.551 -- 4.54x
XWEL
XWELL
-- -0.848 -- 1.72x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRPH
ProPhase Labs
-$165K -$7.9M -47.22% -59.59% -252.29% -$4.2M
APDN
Applied DNA Sciences
$684.1K -$3M -113.07% -113.07% -247.7% -$3.4M
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
OCX
OncoCyte
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M
XWEL
XWELL
$2.1M -$4.6M -71.82% -71.82% -54.82% -$3.8M

ProPhase Labs vs. Competitors

  • Which has Higher Returns PRPH or APDN?

    Applied DNA Sciences has a net margin of -209.38% compared to ProPhase Labs's net margin of -220.57%. ProPhase Labs's return on equity of -59.59% beat Applied DNA Sciences's return on equity of -113.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    APDN
    Applied DNA Sciences
    57.17% -$28.00 $12.5M
  • What do Analysts Say About PRPH or APDN?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4204.43%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 232386.05%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is PRPH or APDN More Risky?

    ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.491%.

  • Which is a Better Dividend Stock PRPH or APDN?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or APDN?

    ProPhase Labs quarterly revenues are $3.1M, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. ProPhase Labs's net income of -$6.6M is lower than Applied DNA Sciences's net income of -$2.6M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.97x versus 0.04x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    0.97x -- $3.1M -$6.6M
    APDN
    Applied DNA Sciences
    0.04x -- $1.2M -$2.6M
  • Which has Higher Returns PRPH or FONR?

    Fonar has a net margin of -209.38% compared to ProPhase Labs's net margin of 9.23%. ProPhase Labs's return on equity of -59.59% beat Fonar's return on equity of 5.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    FONR
    Fonar
    44.52% $0.37 $160.3M
  • What do Analysts Say About PRPH or FONR?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4204.43%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    FONR
    Fonar
    0 0 0
  • Is PRPH or FONR More Risky?

    ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

  • Which is a Better Dividend Stock PRPH or FONR?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or FONR?

    ProPhase Labs quarterly revenues are $3.1M, which are smaller than Fonar quarterly revenues of $27.2M. ProPhase Labs's net income of -$6.6M is lower than Fonar's net income of $2.5M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Fonar's PE ratio is 10.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.97x versus 0.83x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    0.97x -- $3.1M -$6.6M
    FONR
    Fonar
    0.83x 10.81x $27.2M $2.5M
  • Which has Higher Returns PRPH or OCX?

    OncoCyte has a net margin of -209.38% compared to ProPhase Labs's net margin of -312.02%. ProPhase Labs's return on equity of -59.59% beat OncoCyte's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    OCX
    OncoCyte
    61.97% -$0.26 $10.2M
  • What do Analysts Say About PRPH or OCX?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4204.43%. On the other hand OncoCyte has an analysts' consensus of $4.42 which suggests that it could grow by 57.74%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    OCX
    OncoCyte
    1 2 0
  • Is PRPH or OCX More Risky?

    ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

  • Which is a Better Dividend Stock PRPH or OCX?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or OCX?

    ProPhase Labs quarterly revenues are $3.1M, which are larger than OncoCyte quarterly revenues of $2.1M. ProPhase Labs's net income of -$6.6M is higher than OncoCyte's net income of -$6.7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.97x versus 12.69x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    0.97x -- $3.1M -$6.6M
    OCX
    OncoCyte
    12.69x -- $2.1M -$6.7M
  • Which has Higher Returns PRPH or VCYT?

    Veracyte has a net margin of -209.38% compared to ProPhase Labs's net margin of 6.16%. ProPhase Labs's return on equity of -59.59% beat Veracyte's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
  • What do Analysts Say About PRPH or VCYT?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4204.43%. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 39.66%. Given that ProPhase Labs has higher upside potential than Veracyte, analysts believe ProPhase Labs is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    VCYT
    Veracyte
    7 2 1
  • Is PRPH or VCYT More Risky?

    ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

  • Which is a Better Dividend Stock PRPH or VCYT?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or VCYT?

    ProPhase Labs quarterly revenues are $3.1M, which are smaller than Veracyte quarterly revenues of $114.5M. ProPhase Labs's net income of -$6.6M is lower than Veracyte's net income of $7M. Notably, ProPhase Labs's price-to-earnings ratio is -- while Veracyte's PE ratio is 70.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.97x versus 4.95x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    0.97x -- $3.1M -$6.6M
    VCYT
    Veracyte
    4.95x 70.73x $114.5M $7M
  • Which has Higher Returns PRPH or XWEL?

    XWELL has a net margin of -209.38% compared to ProPhase Labs's net margin of -56.4%. ProPhase Labs's return on equity of -59.59% beat XWELL's return on equity of -71.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPH
    ProPhase Labs
    -5.25% -$0.35 $55.3M
    XWEL
    XWELL
    24.38% -$0.99 $14.8M
  • What do Analysts Say About PRPH or XWEL?

    ProPhase Labs has a consensus price target of $13.80, signalling upside risk potential of 4204.43%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 656.76%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPH
    ProPhase Labs
    0 0 0
    XWEL
    XWELL
    0 0 0
  • Is PRPH or XWEL More Risky?

    ProPhase Labs has a beta of -0.472, which suggesting that the stock is 147.175% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

  • Which is a Better Dividend Stock PRPH or XWEL?

    ProPhase Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPH or XWEL?

    ProPhase Labs quarterly revenues are $3.1M, which are smaller than XWELL quarterly revenues of $8.4M. ProPhase Labs's net income of -$6.6M is lower than XWELL's net income of -$4.8M. Notably, ProPhase Labs's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs is 0.97x versus 0.13x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPH
    ProPhase Labs
    0.97x -- $3.1M -$6.6M
    XWEL
    XWELL
    0.13x -- $8.4M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Why Mobileye Might Be Wall Street’s Next Big Surprise
Why Mobileye Might Be Wall Street’s Next Big Surprise

The trend to automate vehicles started long ago when adding…

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
99
SOC alert for May 20

Sable Offshore [SOC] is up 2.18% over the past day.

Buy
52
RGC alert for May 20

Regencell Bioscience Holdings [RGC] is up 22.15% over the past day.

Sell
40
GWLIF alert for May 20

Great-West Lifeco [GWLIF] is up 12.44% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock